Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Antitubercular Agents
/ pharmacology
Diarylquinolines
/ pharmacokinetics
Drug Resistance, Bacterial
Drug Therapy, Combination
Extensively Drug-Resistant Tuberculosis
/ diagnosis
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Mycobacterium tuberculosis
/ drug effects
Nitroimidazoles
/ pharmacology
Oxazoles
/ pharmacology
Treatment Outcome
XDR-tuberculosis
bedaquiline resistance
delamanid resistance
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
13 09 2019
13 09 2019
Historique:
received:
24
10
2018
accepted:
21
01
2019
pubmed:
2
4
2019
medline:
10
9
2020
entrez:
2
4
2019
Statut:
ppublish
Résumé
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
Identifiants
pubmed: 30933266
pii: 5305974
doi: 10.1093/cid/ciz074
doi:
Substances chimiques
Antitubercular Agents
0
Diarylquinolines
0
Nitroimidazoles
0
OPC-67683
0
Oxazoles
0
bedaquiline
78846I289Y
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1229-1231Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.